08Sep 2023
Pfizer and Valneva Report 'Favorable' Outcome for Lyme Disease Vaccine Candidate Booster

Pfizer and Valneva Report 'Favorable' Outcome for Lyme Disease Vaccine Candidate Booster

Pfizer and Valneva report a "strong immune response" in children and adolescents one month after a booster shot in a Phase 2 study of VLA15 Lyme disease vaccine candidate. This promising outcome underscores the vaccine's potential to protect against Lyme disease in young populations. VLA15 was well-tolerated across all age groups following the booster dose. Pfizer plans to submit regulatory applications for VLA15 to the European Medicines Agency and U.S. FDA by 2026, pending positive results from the ongoing phase 3 clinical trial. This vaccine is hailed as the most advanced in Lyme disease prevention.

  • #family health

Like

Save

Share